Biogen Idec has sold its royalty and other rights relating to Benlysta (belimumab), for treating systemic lupus erythematosus, to a DRI Capital-managed fund. Biogen Idec’s entitlement results from a license agreement with the GlaxoSmithKline subsidiaries Human Genome Sciences (HGS) and Glaxo Group Limited. Under the agreement between Biogen Idec and DRI, HGS and Glaxo Group Limited will make royalty payments directly to DRI instead of to Biogen Idec. DRI will in turn pay Biogen Idec a multiple of certain of the royalties received for the period covering October 2011 to September 2014. Following that period, DRI will retain the royalty payments from the sales of Benlysta, with certain exceptions, including a one-time contingency payment that could be triggered if the cumulative royalties to DRI exceed an agreed amount. Read More

Advertisement: The FDA has taken the next step in increasing efficiency of electronic regulatory reporting through the implementation of the eMDR Electronic Submissions Gateway. Learn the benefits and best practices of using the FDA's eMDR program to meet specific business needs, and the future of eMDR for Life Science organizations. Read More

Cambridge Major Laboratories (CML) is planning a significant expansion of its large-scale API manufacturing facility in Germantown, Wisconsin. The expansion comes three years after commissioning the new site. The expansion will include additional reactor capacity as well as isolation equipment. Alongside capacity additions, CML has made additional investments in engineering controls to ensure the sustainability of the business. Read More

Advertisement: Free Technical Posters for Tablet Manufacturers The latest edition to Natoli's extensive collection of free technical resources, the Technical Poster Series features 3 large-format posters packed with helpful tips, charts, terminology, and more. For a limited time, all 3 posters are available at no charge — shipping included — so order yours now! http://www.natoli.com/Posters-PT.html

Spectrum Pharmaceuticals has completed the acquisition of Allos Therapeutics on Sept. 5, 2012 through a short-form merger of Sapphire Acquisition Sub, a wholly owned subsidiary of Spectrum, with and into Allos, with Allos surviving the merger and continuing as a wholly-owned subsidiary of Spectrum. Read More

Advertisement: Realize Effective Pharmaceuticals Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market www.agilent.com/lifesciences/realizepharma

Takeda Pharmaceutical has completed construction of its pharmaceutical manufacturing facility in Yaroslavl, Russia. The company has invested approximately EUR 75 million ($96.4 million) in the 24,000-m² (258,334 ft²) production plant, which the company expects to be fully operational by 2014. The plant will have initial capacity to manufacture 90 million ampuls and more than two billion tablets per year.

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

Advertisement: Recent USP Changes: Regulatory and Quality Aspects of Sample Preparation Live Webcast: Tuesday, September 18 2012 at 11:00 AM EDT www.pharmtech.com/sampleprep